skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine

Abstract

We investigated the serotype- and topotype versatility of a replication-deficient human adenovirus serotype 5 vectored foot-and-mouth disease (FMD) vaccine platform (AdtFMD). Sixteen AdtFMD recombinant subunit monovalent vaccines targeting twelve distinct FMD virus (FMDV) serotype/topotypes in FMD Regional Pools I-VII were constructed. The AdtA24 serotype conditionally licensed vaccine served as the basis for vaccine design and target dose for cattle clinical trials. Several vaccines contained an additional RGD motif genetic insertion in the adenovector fiber knob, and/or a full-length 2B gene insertion in the FMDV P1 gene cassette. In 13 of the 22 efficacy studies conducted, naïve control and AdtFMD vaccinated cattle were challenged intradermolingually at 2 weeks post-vaccination using a FMDV strain homologous to the AdtFMD vaccine strain. Each of the 16 AdtFMD vaccines were immunogenic based on the presence of homologous neutralizing antibodies in the serum of approximately 90% of total vaccinates (n = 375) on the day of challenge. Importantly, for 75% of vaccines tested, the effective dose that conferred 100% protection against clinical FMD was identical to or in some cases lower than, the minimum protective dose for the conditionally licensed AdtA24 vaccine formulated with ENABL® adjuvant. Results also confirmed the capability of the AdtFMD vaccine platformmore » to differentiate infected from vaccinated animals (DIVA) across the five FMDV serotypes evaluated. Collectively, this comprehensive set of FMD cattle vaccine dose ranging studies highlights the serotype- and topotype versatility of the AdtFMD vaccine platform for further development, licensure, and application in FMD outbreak control and disease eradication efforts.« less

Authors:
 [1];  [1];  [1];  [2]; ORCiD logo [1];  [1];  [3];  [1];  [4];  [1];  [2];  [2];  [1]; ORCiD logo [1]
  1. Plum Island Animal Disease Center, Greenport, NY (United States)
  2. GenVec, Inc., Gaithersburg, MD (United States)
  3. Plum Island Animal Disease Center Research Participation Program, Oak Ridge, TN (United States). Oak Ridge Institute for Science and Education
  4. Plum Island Animal Disease Center, Greenport, NY (United States); Plum Island Animal Disease Center Research Participation Program, Oak Ridge, TN (United States). Oak Ridge Institute for Science and Education
Publication Date:
Research Org.:
Oak Ridge Inst. for Science and Education (ORISE), Oak Ridge, TN (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1494688
Grant/Contract Number:  
AC05-06OR23100; HSHQPD-07-X-00003; HSHQDC-14-F-00035; HSHQDC-8-C-00011; HSHQDC-12-C-00127
Resource Type:
Journal Article: Accepted Manuscript
Journal Name:
Vaccine
Additional Journal Information:
Journal Volume: 36; Journal Issue: 48; Journal ID: ISSN 0264-410X
Publisher:
Elsevier
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES; 60 APPLIED LIFE SCIENCES; Foot-and-mouth disease virus; Recombinant human adenovirus vectored vaccine; Serotype; Vaccine efficacy; DIVA; Cattle

Citation Formats

Barrera, José, Brake, David A., Schutta, Christopher, Ettyreddy, Damodar, Kamicker, Barbara J., Rasmussen, Max V., Bravo de Rueda, Carla, Zurita, Mariceny, Pisano, Melia, Hurtle, William, Brough, Douglas E., Butman, Bryan T., Harper, Bruce G., and Neilan, John G. Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine. United States: N. p., 2018. Web. doi:10.1016/j.vaccine.2018.10.031.
Barrera, José, Brake, David A., Schutta, Christopher, Ettyreddy, Damodar, Kamicker, Barbara J., Rasmussen, Max V., Bravo de Rueda, Carla, Zurita, Mariceny, Pisano, Melia, Hurtle, William, Brough, Douglas E., Butman, Bryan T., Harper, Bruce G., & Neilan, John G. Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine. United States. doi:10.1016/j.vaccine.2018.10.031.
Barrera, José, Brake, David A., Schutta, Christopher, Ettyreddy, Damodar, Kamicker, Barbara J., Rasmussen, Max V., Bravo de Rueda, Carla, Zurita, Mariceny, Pisano, Melia, Hurtle, William, Brough, Douglas E., Butman, Bryan T., Harper, Bruce G., and Neilan, John G. Sat . "Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine". United States. doi:10.1016/j.vaccine.2018.10.031. https://www.osti.gov/servlets/purl/1494688.
@article{osti_1494688,
title = {Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine},
author = {Barrera, José and Brake, David A. and Schutta, Christopher and Ettyreddy, Damodar and Kamicker, Barbara J. and Rasmussen, Max V. and Bravo de Rueda, Carla and Zurita, Mariceny and Pisano, Melia and Hurtle, William and Brough, Douglas E. and Butman, Bryan T. and Harper, Bruce G. and Neilan, John G.},
abstractNote = {We investigated the serotype- and topotype versatility of a replication-deficient human adenovirus serotype 5 vectored foot-and-mouth disease (FMD) vaccine platform (AdtFMD). Sixteen AdtFMD recombinant subunit monovalent vaccines targeting twelve distinct FMD virus (FMDV) serotype/topotypes in FMD Regional Pools I-VII were constructed. The AdtA24 serotype conditionally licensed vaccine served as the basis for vaccine design and target dose for cattle clinical trials. Several vaccines contained an additional RGD motif genetic insertion in the adenovector fiber knob, and/or a full-length 2B gene insertion in the FMDV P1 gene cassette. In 13 of the 22 efficacy studies conducted, naïve control and AdtFMD vaccinated cattle were challenged intradermolingually at 2 weeks post-vaccination using a FMDV strain homologous to the AdtFMD vaccine strain. Each of the 16 AdtFMD vaccines were immunogenic based on the presence of homologous neutralizing antibodies in the serum of approximately 90% of total vaccinates (n = 375) on the day of challenge. Importantly, for 75% of vaccines tested, the effective dose that conferred 100% protection against clinical FMD was identical to or in some cases lower than, the minimum protective dose for the conditionally licensed AdtA24 vaccine formulated with ENABL® adjuvant. Results also confirmed the capability of the AdtFMD vaccine platform to differentiate infected from vaccinated animals (DIVA) across the five FMDV serotypes evaluated. Collectively, this comprehensive set of FMD cattle vaccine dose ranging studies highlights the serotype- and topotype versatility of the AdtFMD vaccine platform for further development, licensure, and application in FMD outbreak control and disease eradication efforts.},
doi = {10.1016/j.vaccine.2018.10.031},
journal = {Vaccine},
issn = {0264-410X},
number = 48,
volume = 36,
place = {United States},
year = {2018},
month = {10}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record

Citation Metrics:
Cited by: 1 work
Citation information provided by
Web of Science

Figures / Tables:

Table 1 Table 1: Replication deficient AdtFMD vaccine constructs evaluated for cattle efficacy.

Save / Share:
Figures/Tables have been extracted from DOE-funded journal article accepted manuscripts.